Liver transplantation and immune tolerance:Setting the stage for optimal post-transplant status  

作　　者：Jiaying Cao Qi Ling 

机构地区：[1]Department of Surgery,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310000,China [2]NHC Key Laboratory of Combined Multi-organ Transplantation,Hangzhou 310000,China [3]State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,National Medical Center for Infectious Diseases,Hangzhou 310000,China

出　　处：《iLIVER》2024年第2期1-2,共2页国际肝胆健康（英文）

基　　金：supported by the National Natural Science Foundation of China(Nos 82171757 and 82241215);the Natural Science Foundation of Zhejiang Province(LZ22H030004).

摘　　要：1.Introduction Liver transplantation(LT)has emerged as the primary treatment for various end-stage liver diseases.Immunosuppression is essential to reduce the incidence of acute rejection.The development of modern immunosuppressive agents such as calcineurin inhibitor(CNI)leads to the improved short-term survivals for both grafts and recipients.However,immunosuppressive agents have toxicities and cause clinicalrelevant side effects including de novo cancers,infections,metabolic syndrome,renal failure,cardiovascular attack,and graft fibrosis[1].Long-term outcomes are affected by a variety of chronic complications such as progressive loss of graft function and biliary non-anastomotic stricture,which also appear to be correlated to the graft-specific immune response.

关 键 词：LIVER ACUTE GRAFT 

分 类 号：R657.3[医药卫生—外科学]